^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

IDH1 mutation

i
Other names: HEL-216, HEL-S-26, Epididymis Luminal Protein 216, Isocitrate Dehydrogenase 1 (NADP+), Epididymis Secretory Protein Li 26, IDH1, Isocitrate Dehydrogenase (NADP(+)) 1, Isocitrate Dehydrogenase 1 (NADP+), Soluble
Entrez ID:
Related biomarkers:
IDH1 mutation
Acute Myelogenous Leukemia
ivosidenib
Sensitive
:
A1
SOHO 2022 - 1 week - (New C3)
IDH1 mutation
Myelodysplastic Syndrome
venetoclax + ivosidenib
Sensitive
:
C3
SOHO 2022 - 1 week - (New C3)
IDH1 mutation
Acute Myelogenous Leukemia
MEN1703
Sensitive
:
C3
SOHO 2022 - 1 week - (New C3)
IDH1 mutation
Cholangiocarcinoma
ivosidenib
Sensitive
:
A1
Target Oncol - 2 weeks - (New C4)
IDH1 mutation
Astrocytoma
temozolomide
Sensitive
:
A2
IDH1 mutation
Acute Myelogenous Leukemia
venetoclax
Sensitive
:
A2
IDH1 mutation
Sarcoma
ivosidenib
Sensitive
:
A2
IDH1 mutation
Astrocytoma
PCV
Sensitive
:
A2
IDH1 mutation
Astrocytoma
cisplatin
Sensitive
:
A2
IDH1 mutation
Astrocytoma
carboplatin
Sensitive
:
A2
IDH1 mutation
Astrocytoma
etoposide IV
Sensitive
:
A2
IDH1 mutation
Astrocytoma
bevacizumab
Sensitive
:
A2
IDH1 mutation
Astrocytoma
carmustine
Sensitive
:
A2
IDH1 mutation
Astrocytoma
lomustine
Sensitive
:
A2
IDH1 mutation
Glioma
temozolomide gel
Sensitive
:
B
IDH1 mutation
Acute Myelogenous Leukemia
gilteritinib
Resistant
:
B
IDH1 mutation
Glioma
temozolomide
Sensitive
:
B
IDH1 mutation
Glioma
PCV
Sensitive
:
B
IDH1 mutation
Glioma
ivosidenib
Sensitive
:
C1
IDH1 mutation
Myelodysplastic Syndrome
ivosidenib
Sensitive
:
C1
IDH1 mutation
Glioblastoma
temozolomide
Sensitive
:
C2
IDH1 mutation
Glioblastoma
NEO100
Sensitive
:
C2
IDH1 mutation
Glioma
S095032
Sensitive
:
C2
IDH1 mutation
Glioma
TG02
Sensitive
:
C3
IDH1 mutation
Acute Myelogenous Leukemia
cytarabine / daunorubicin liposomal formulation
Sensitive
:
C3
IDH1 mutation
Acute Myelogenous Leukemia
venetoclax + ABBV-621
Sensitive
:
C3
IDH1 mutation
Acute Myelogenous Leukemia
venetoclax + ivosidenib
Sensitive
:
C3
IDH1 mutation
Acute Myelogenous Leukemia
FT-2102
Sensitive
:
C3
IDH1 mutation
Glioblastoma
pembrolizumab
Resistant
:
C3
IDH1 mutation
Acute Myelogenous Leukemia
CFI-400945
Sensitive
:
C3
IDH1 mutation
Acute Myelogenous Leukemia
venetoclax + midostaurin
Resistant
:
C3
IDH1 mutation
Acute Myelogenous Leukemia
venetoclax + gilteritinib
Resistant
:
C3
IDH1 mutation
Acute Myelogenous Leukemia
venetoclax + sorafenib
Resistant
:
C3
IDH1 mutation
Chronic Myelomonocytic Leukemia
venetoclax
Sensitive
:
C3
IDH1 mutation
Glioma
BAY1436032
Sensitive
:
C3
IDH1 mutation
Anaplastic Astrocytoma
PCV
Sensitive
:
C3